Shots:

• Resolution to receive $550M in cash at closing and ~$145M following the achievement of certain milestones. The transaction is expected to close in Apr’2021
• The acquisition will expand Agilent’s capabilities in NGS-based cancer diagnostics and strengthen its position in precision oncology testing globally
• The acquisition will bring together Resolution’s noninvasive liquid biopsy platform that improves cancer diagnostics with Agilent’s leadership in tissue-based CDx and global commercial and regulatory scale

 ­ Ref: Agilent | Image: Resolution Bio